重新审视黑色素瘤中部分PTEN缺失的临床与生物学相关性
研究在190例III期黑色素瘤前瞻性随访队列中以免疫组化评估PTEN表达,发现弱表达与缺失表达均预测更短生存(风险比=2.13,P<0.01)。PTEN基因组改变、启动子甲基化及蛋白失稳不能完全解释PTEN缺失,而组蛋白去乙酰化酶抑制剂LBH589处理可提高PTEN水平,提示部分PTEN缺失由可调控的表观遗传机制所致并驱动Akt激活与不良预后。
要点
- 190例III期黑色素瘤中,PTEN强表达21例(11%)、中等51例(27%)、弱44例(23%)、缺失74例(39%)。
- 弱与缺失PTEN表达在多因素分析中均预测更短生存(风险比=2.13,P<0.01)。
- 部分PTEN缺失由可调控的表观遗传机制所致,驱动Akt激活并提示改善部分晚期患者结局的潜在途径。
核心结论
- 部分PTEN缺失由可调控的表观遗传机制所致,驱动Akt激活并导致更差预后,提示改善部分晚期黑色素瘤患者临床结局的潜在途径。
研究设计与样本
- 在190例III期黑色素瘤前瞻性随访队列中以免疫组化评估PTEN表达,并分析PTEN基因组改变、启动子甲基化、蛋白失稳及LBH589处理对PTEN水平的影响。
主要发现
- 190例中PTEN强表达21例(11%)、中等51例(27%)、弱44例(23%)、缺失74例(39%)。
- 弱与缺失PTEN表达在多因素分析中均预测更短生存(风险比=2.13,P<0.01)。
- 在滴定PTEN表达的黑色素瘤细胞及两个额外独立肿瘤数据集中,PTEN与活化Akt呈连续负相关。
- PTEN基因组改变(缺失、突变)、启动子甲基化及蛋白失稳不能完全解释黑色素瘤中的PTEN缺失,而组蛋白去乙酰化酶抑制剂LBH589处理黑色素瘤细胞后PTEN水平升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The extent of PTEN loss that confers clinical and biological impact in melanoma is unclear. We evaluated the clinical and biologic relevance of PTEN dosage in melanoma and tested the postulate that partial PTEN loss is due to epigenetic mechanisms. PTEN expression was assessed by immunohistochemistry in a stage III melanoma cohort (n = 190) with prospective follow up. Overall, 21 of 190 (11%) tumors had strong PTEN expression, 51 of 190 (27%) had intermediate PTEN, 44 of 190 (23%) had weak PTEN, and 74 of 190 (39%) had absent PTEN. Both weak and absent PTEN expression predicted shorter survival in multivariate analyses (hazard ratio = 2.13, P < 0.01). We show a continuous negative correlation between PTEN and activated Akt in melanoma cells with titrated PTEN expression and in two additional independent tumor datasets. PTEN genomic alterations (deletion, mutation), promoter methylation, and protein destabilization did not fully explain PTEN loss in melanoma, whereas PTEN levels increased with treatment of melanoma cells with the histone deacetylase inhibitor LBH589. Our data indicate that partial PTEN loss is due to modifiable epigenetic mechanisms and drives Akt activation and worse prognosis, suggesting a potential approach to improve the clinical outcome for a subset of patients with advanced melanoma.
引用
- Giles KM, Rosenbaum BE, Berger M, et al. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma. J Invest Dermatol. 2018. PMID: 30148988. doi:10.1016/j.jid.2018.07.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。